Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

2yrs ago Private Equity privateequitywire Views: 200

IW Capital invests in e-pharmacy platform SimplyMeds

Submitted 13/07/2021 - 10:34am

IW Capital has invested in e-pharmacy company SimplyMeds, marking the first external investment in the highly scalable online platform.

SimplyMeds is an end-to-end digital pharmacy platform that provides a convenient method of ordering same day prescriptions and lifestyle products while empowering patients to have medical autonomy. While most online pharmacies are designed to service only one sector, SimplyMeds caters to both the private and NHS prescriptions market in what is believed to be a market first, having developed the distribution channels and a highly sophisticated platform to effectively serve both sectors. 

Bootstrapped by two entrepreneurs with extensive experience in the pharmaceutical industry – one a prescribing pharmacist and one a dentist - the company has grown organically over the last five years from a spare room in a surgery to a material player in London and the South East, with minimal marketing and no external investment prior to IW Capital's deal.

With a strong growth plan targeting revenue in excess of GBP6 million over the next 18 months, IW Capital's funding will accelerate SimplyMeds' development and advance its international market potential through an expansion of distribution channels and a comprehensive sales and marketing spend. 

The e-pharmacy market has been growing year on year for the last five years, and the pandemic has only served to accelerate this trajectory as both doctors and consumers increasingly seek online methods of obtaining over-the-counter, prescription and lifestyle products. Global spending on pharmaceutical products is set to reach USD1.7 trillion by 2026, and the e-pharmacy market specifically is forecast to reach a CAGR of between 14.22 per cent and 17.3 per cent for the next six to eight years as consumers become ever more reliant on online service providers.

The experienced entrepreneurial management team behind SimplyMeds have a proven exit track record and believe the company is ready for significant scaling.

Dr Saranjit Sihra, Co-Founder of Simply Meds, says: "We are very thrilled to have IW Capital onboard in helping us grow the business further and expand our potential nationally as the trusted go-to pharmacy service in the UK.” 
 
Parvinder Sagoo, Co-Founder of Simply Meds, says: “We believe that we are ready to take the next huge leap in our journey and that IWC can help us achieve huge success in our sector. There are very exciting times ahead.”
 
Douglas Lidgit, Investment Director of IW Capital, says: “We are excited to be part of the growth story of SimplyMeds. The Founders, Parv and Sunny, have built an extremely successful platform and our investment will enable them to grow the business materially in the next 5 years.”

Like this article? Sign up to our free newsletter Related Topics Deals & Transactions Healthcare & Life Sciences Retail & Leisure Investments

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.